One-day rejuvenation: a preliminary case series of a multimodal protocol combining Q-switched 1064 nm laser, botulinum toxin, and laser-assisted delivery of PDRN and retinoids.

Authors

Rafael Rodrigo Crisanto de Oliveira

Published in

Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology. Pages 1-4. Jul 08, 2026. Epub Jul 08, 2026.

Abstract

Same-day multimodal aesthetic treatments may optimize patient convenience, but concerns remain regarding possible thermal degradation of botulinum toxin type A (BoNT-A) when combined with energy-based devices. To preliminarily evaluate the feasibility and clinical outcomes of a single-session protocol combining Q-switched (QS) 1064 nm laser, incobotulinumtoxinA, and laser-assisted drug delivery (LADD) of polydeoxyribonucleotide (PDRN) and retinoic acid. This pilot case series included five patients. The protocol consisted of carbon-assisted QS 1064 nm laser treatment (2 J/cm), immediately followed by intramuscular BoNT-A injections and topical application of 5% PDRN and 10% retinoic acid. Outcomes were assessed 15 days post-treatment using the Modified Fitzpatrick Wrinkle Scale (MFWS) and Global Aesthetic Improvement Scale (GAIS). Clinical follow-up was performed for up to 6 months. Mean MFWS scores improved from 1.96 ± 0.46 to 0.88 ± 0.39 (p < .001). All patients were rated as "Much Improved" or "Very Much Improved" on GAIS. No serious adverse events occurred. BoNT-A efficacy was clinically preserved throughout follow-up. This multimodal protocol appears to be a feasible and well-tolerated strategy for same-session facial rejuvenation without clinically compromising BoNT-A efficacy.

PMID:
42418230
Bibliographic data and abstract were imported from PubMed on 08 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.